Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $7.8 million.

  • Protalix BioTherapeutics' Operating Expenses rose 589.99% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.7 million, marking a year-over-year decrease of 893.52%. This contributed to the annual value of $25.2 million for FY2024, which is 2149.32% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Operating Expenses of $7.8 million as of Q3 2025, which was up 589.99% from $4.7 million recorded in Q2 2025.
  • Protalix BioTherapeutics' Operating Expenses' 5-year high stood at $11.9 million during Q1 2022, with a 5-year trough of $4.7 million in Q2 2025.
  • Moreover, its 5-year median value for Operating Expenses was $8.5 million (2023), whereas its average is $8.5 million.
  • In the last 5 years, Protalix BioTherapeutics' Operating Expenses surged by 1618.91% in 2022 and then tumbled by 3826.32% in 2025.
  • Protalix BioTherapeutics' Operating Expenses (Quarter) stood at $11.1 million in 2021, then fell by 21.54% to $8.7 million in 2022, then dropped by 16.87% to $7.2 million in 2023, then dropped by 1.68% to $7.1 million in 2024, then increased by 9.36% to $7.8 million in 2025.
  • Its last three reported values are $7.8 million in Q3 2025, $4.7 million for Q2 2025, and $6.1 million during Q1 2025.